November 28, 2007
FDA Cites Glaxo For Misleading "Dear Doctor" Letters
The FDA has issued a warning letter to GlaxoSmithKline for misleading "Dear Doctor" letters on the drug Tykerb, a daily pill for patients with advanced breast cancer. As CNNMoney (via AP) reports, the FDA asserts that the "Dear Doctor" letters omit the drug's risks and further exaggerate the drug's effectiveness.
TrackBack URL for this entry:
Listed below are links to weblogs that reference FDA Cites Glaxo For Misleading "Dear Doctor" Letters: